SciBrunch

MSD licenses a KRAS G12D-targeting drug from China’s SciBrunch under a $2.13 billion oncology partnership. The deal reflects growing pharmaceutical investment in RAS protein therapies, which regulate cell growth and division. KRAS mutations drive multiple cancers, making targeted treatments a high-priority area in oncology research.

Sep 2026healthcaremea.comNews article

Merck secures global rights to SciBrunch Therapeutics’ **SPR2015**, a preclinical oral inhibitor targeting **KRAS G12D**, under a collaboration valued up to **$2.13 billion**. The deal focuses on advancing this **molecular glue** approach for potential cancer treatments. SciBrunch retains development and commercialization rights in Japan.

Sep 2026GEN - Genetic Engineering and Biotechnology NewsNews article

Merck secures exclusive licensing rights to SciBrunch’s experimental cancer therapy under a deal potentially worth up to **$2.13 billion**. The agreement grants Merck global commercialization access to the drug candidate, though financial terms beyond the cap remain undisclosed. SciBrunch retains development oversight while Merck handles late-stage trials and potential regulatory submissions. The partnership accelerates SciBrunch’s oncology pipeline without requiring upfront capital investment.

Sep 2026ETPharma.comNews article

Merck & Co. secures exclusive global rights to SciBrunch Therapeutics’ preclinical oral KRAS G12D inhibitor, SPR2015, under a $2.13 billion licensing deal. The agreement strengthens Merck’s oncology pipeline by adding a novel KRAS-targeting therapy. SciBrunch retains development and commercialization rights in China.

Sep 2026BiotechReality - Information Intelligence System for BiopharmaNews article